share_log

EXCLUSIVE: Pasithea Therapeutics Announces Results Of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy In Relapsing-Remitting Model Multiple Sclerosis

EXCLUSIVE: Pasithea Therapeutics Announces Results Of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy In Relapsing-Remitting Model Multiple Sclerosis

独家报道:Pasithea Treateutics宣布临床前研究结果表明,耐受疫苗对复发-缓解型多发性硬化症有效
Benzinga Real-time News ·  2022/08/11 07:30

EXCLUSIVE: Pasithea Therapeutics Announces Results Of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy In Relapsing-Remitting Model Multiple Sclerosis

独家报道:Pasithea Treateutics宣布临床前研究结果表明,耐受疫苗对复发-缓解型多发性硬化症有效

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发